- Previous Close
36.45 - Open
37.30 - Bid 37.40 x --
- Ask 38.00 x --
- Day's Range
37.30 - 37.30 - 52 Week Range
29.90 - 42.68 - Volume
60 - Avg. Volume
118 - Market Cap (intraday)
2.055B - Beta (5Y Monthly) 1.14
- PE Ratio (TTM)
22.20 - EPS (TTM)
1.68 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield 0.88 (2.57%)
- Ex-Dividend Date Jun 28, 2024
- 1y Target Est
47.62
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals. The company also provides vitamins, minerals, food supplements, as well as products for dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. In addition, it offers cosmetics and medical devices. Further, the company imports originator pharmaceuticals under the axicorp brand. It sells its products under the Dekristol, Keltican, Tromcardin, Ketozolin, bite away, Herpotherm, and epiivo brands. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.
ir.dermapharm.de3,603
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DMP.F
View MorePerformance Overview: DMP.F
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DMP.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DMP.F
View MoreValuation Measures
Market Cap
1.96B
Enterprise Value
2.88B
Trailing P/E
21.70
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.70
Price/Book (mrq)
3.36
Enterprise Value/Revenue
2.49
Enterprise Value/EBITDA
9.65
Financial Highlights
Profitability and Income Statement
Profit Margin
7.24%
Return on Assets (ttm)
5.71%
Return on Equity (ttm)
15.00%
Revenue (ttm)
1.15B
Net Income Avi to Common (ttm)
83.04M
Diluted EPS (ttm)
1.68
Balance Sheet and Cash Flow
Total Cash (mrq)
165.76M
Total Debt/Equity (mrq)
193.81%
Levered Free Cash Flow (ttm)
155.19M